OncoMatch/Clinical Trials/NCT05075460

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Is NCT05075460 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Tucidinostat, Azacitidine combined with CHOP for t-cell lymphoma.

Phase 3RecruitingPeking Union Medical College HospitalNCT05075460Data as of May 2026

Treatment: Tucidinostat, Azacitidine combined with CHOP — This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Excluded: ALK positive

ALK positive anaplastic T-cell lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

WBC > 3.5 × 10^9/L, ANC > 1.5 × 10^9/L, HGB > 90g/L, PLT > 80 × 10^9/L

Kidney function

SCr > 60ml/min/m2

Liver function

ALT < 3UNL, TBil < 2ULN

Cardiac function

cardiac function grade 0-2 (NYHA); SpO2 > 88% (natural condition)

Adequate bone marrow hematopoietic function: WBC > 3.5 × 10*9/L，ANC>1.5 × 10*9/L，HGB>90g/L，PLT>80 × 10*9/L; Adequate organ function: cardiac function grade 0-2 (NYHA); SpO2 > 88% (natural condition); ALT<3UNL，TBil<2ULN; SCr>60ml/min/m2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify